Search results

This guideline covers diagnosing and managing age-related macular degeneration (AMD) in adults. It aims to improve the speed at which people are diagnosed and treated to prevent loss of sight.

Result type

NICE guideline

Published

23 January 2018

Evidence-based recommendations on brolucizumab (Beovu) for treating wet age-related macular degeneration in adults.

Result type

Technology appraisal guidance

Published

3 February 2021

Evidence-based recommendations on faricimab (Vabysmo) for wet age-related macular degeneration in adults.

Result type

Technology appraisal guidance

Published

29 June 2022

Advice on the use of Cellvizio confocal endomicroscopy system (CLS) for characterising pancreatic cysts to aid local decision-making

Result type

Medtech innovation briefing

Published

28 June 2016

Evidence-based recommendations on miniature lens system implantation for advanced age-related macular degeneration. This involves implanting an artificial lens system into 1 eye only.

Result type

Interventional procedures guidance

Published

28 September 2016

NICE has developed a medtech innovation briefing (MIB) on TearLab osmolarity system for diagnosing dry eye disease .

Result type

Medtech innovation briefing

Published

15 December 2015

Evidence-based recommendations on arteriovenous crossing sheathotomy for branch retinal vein occlusion. This involves cutting the sheath around the vessels and physically separating them where they cross to improve blood flow through the vein.

Result type

Interventional procedures guidance

Published

24 March 2010

Evidence-based recommendations on ranibizumab (Lucentis) and pegaptanib (Macugen) for treating wet age-related macular oedema in adults.

Result type

Technology appraisal guidance

Last updated

1 May 2012

Evidence-based recommendations on ciclosporin (Ikervis) for dry eye disease in adults that has not improved despite treatment with artificial tears.

Result type

Technology appraisal guidance

Published

16 December 2015